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Inappropriate use and overuse of antibiotics are among the most important factors in resistance devel-
opment, and effective antibiotic stewardship measures are needed to optimize outcomes. Selection of
appropriate antimicrobials relies on accurate and timely antimicrobial susceptibility testing. However, the
availability of clinical breakpoints and in vitro susceptibility testing often lags behind regulatory approval
by several years for new antimicrobials. A Working Group of clinical/medical microbiologists from Brazil,
Canada, Mexico, Saudi Arabia, Russia and the UK recently examined issues surrounding antimicrobial sus-
ceptibility testing for novel antibiotics. While commercially available tests are being developed, potential
surrogate antibiotics may be used as marker of susceptibility. Using tedizolid as an example of a new
antibiotic, this special report makes recommendations to optimize routine susceptibility reporting.
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Widespread use and misuse of antibiotics have been associated with the selection and spread of antibiotic-resistant
strains in both humans and animals. Antimicrobial resistance nowposes a significant threat to public health across the
world, with alarming increases in the number of infections due to multidrug-resistant pathogens [1]. Consequently,
availability of new antimicrobials is now a critical unmet need. In an effort to promote the development of new,
more active antibiotics, the WHO recently published its first list of antibiotic-resistant ‘priority pathogens’ divided
into three categories – critical, high and medium. It is hoped that the publication of this list will help guide research
toward pathogens that present the greatest risks to public health [2].
While research on antibiotics to combatmultidrug-resistantGram-negative pathogens (e.g., carbapenem-resistant
Enterobacteriaceae) is recognized as being a critical need, high priority is also given to Gram-positive bacteria, which
remain amajor cause of nosocomial infections [2,3].Methicillin-resistant Staphylococcus aureus (MRSA), in particular,
is a prevalent threat in many parts of the world, and is often associated with significant morbidity and mortality,
particularly in the elderly [4,5]. While vancomycin has been the mainstay of treatment for the management ofMRSA
infections [6], therapeutic failures have been reported for isolates possessing minimum inhibitory concentrations
(MICs) >1.5 μg/ml [7–9]. In addition, a loading dose of vancomycin is recommended and therapeutic drug
monitoring required to optimize outcomes, so complicating clinical use [10], particularly in low-resource settings.
The high activity of the novel oxazolidinone antibiotic tedizolid against Gram-positive bacteria, including MRSA
and vancomycin-resistant enterococci, presents a new treatment option for these challenging pathogens, providing
more potent activity than linezolid in vitro [11–14]. Although the optrA gene in some strains of Enterococci may
confer elevated MICs to both tedizolid and linezolid [15–17], this mechanism has not yet been identified in MRSA.
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Noninferiority of tedizolid phosphate (given for 6 days) versus linezolid (10 days) has been demonstrated in two
Phase III studies in patients with acute bacterial skin and skin structure infections [18,19].
Inappropriate use and overuse of antibiotics are among the most important factors in the development of
resistance, and effective antibiotic stewardship measures are needed to optimize the use of antimicrobials [20]. This
includes use of restrictive reporting, and/or encouraging diverse prescribing to avoid overuse of valuable antibiotics
and help control the increase in antimicrobial resistance. Clinicians’ ability to select appropriate antimicrobials relies
on accurate and timely antimicrobial susceptibility testing (AST), a process designed to predict clinical efficacy [20].
However, performing effective AST is challenging, particularly for newly approved antibiotics, since availability of
clinical breakpoints and inclusion on commercial panels and/or access to other in vitro susceptibility materials often
lag behind regulatory approval by several years [1]. Obtaining sufficient clinical data to enable clinical breakpoints
for new agents to be established is also problematic. A Working Group of clinical/medical microbiologists from
Brazil, Canada, Mexico, Saudi Arabia, Russia and the UK was convened to examine issues surrounding AST for
novel antibiotics. This article summarizes their recommendations for optimal routine reporting of susceptibility to
new antibiotics, using the novel oxazolidinone antibiotic tedizolid as an exemplar.
Overview of testing methodology
In recent years, few new Gram-positive directed antibiotics have become available, with only dalbavancin hy-
drochloride, oritavancin and tedizolid phosphate being approved over the past 5 years [21–26]. In order to select the
optimal therapy for their patients, clinicians must be aware of changes in resistance patterns and the effectiveness
of the antibiotics used to treat particular organisms over time. For this reason, a number of global antimicrobial
surveillance programs, including STAR (Surveillance of Tedizolid Activity and Resistance; tedizolid), SOAR (Survey
of Antibiotic Resistance; amoxicillin/clavulanic acid, cefuroxime, cefaclor, azithromycin and ofloxacin), ZAAPS
(Zyvox R© Annual Appraisal of Potency and Spectrum; linezolid) and TEST (Tigecycline Evaluation Surveillance
Trial; tigecycline), have been initiated [27–31].
Susceptibility testing can be either automated (e.g., Vitek2, Microscan and Phoenix), or manual (e.g., disk
diffusion [as recommended by the European Committee on Antimicrobial Susceptibility Testing – EUCAST –
or Clinical and Laboratory Standards Institute – CLSI], broth microdilution or gradient testing [e.g., E-test R©]).
Each system has advantages and limitations, with some providing quality control ranges [1,32–35]. Working Group
members report that the majority of laboratories in their countries use automated testing systems routinely for
susceptibility testing, most of which provide MICs. Manual testing is frequently used to confirm automated AST
results and/or MICs; E-test R© and disk diffusion are the preferred methods, with the latter being the more fa-
vored choice in cost-conscious environments. Of note, in routine susceptibility testing, vancomycin MICs may
not reflect accurately the actual MICs and their confirmation by E-test R© has recently been recommended to
minimize the risk of treatment failure [36]. Determination of MICs is important for certain strains not identified
by an automated system or disk diffusion (e.g., vancomycin-intermediate S. aureus [VISA]). Failure with empiric
vancomycin treatment in a Saudi 69-year-old male patient, for example, prompted physicians to obtain more
accurate susceptibility data on the pathogen isolated from blood. This led to the discovery of the first heteroge-
neous vancomycin-intermediate Staphylococcus aureus (hVISA), a threatening signal to the effectiveness of empiric
vancomycin treatment in hospitalized patients with severe infections [37].
Effective performance of AST by clinical microbiology laboratories is essential in order to determine susceptibility
to the chosen empirical antimicrobial agents, and to detect the emergence of resistance [38]. Use of susceptibility
breakpoints (e.g., those provided by the CLSI and EUCAST) is important, both for consistent reporting of antimi-
crobial susceptibility and for consistency and comparability of international surveillance schemes [39]. EUCAST and
CLSI also advocate use of epidemiological cut-off values as one of several tools in the process of establishing clinical
breakpoints; determination of such cut-off values may promote more susceptibility testing and allow MIC values
to be put into context [40]. While most laboratories follow either CLSI or EUCAST breakpoints for susceptibility
testing, some may use both if a pathogen is not included in the guidelines they normally follow. When there is
no available information on appropriate clinical breakpoints for certain bacteria, physicians may rely on their best
judgment with regard to MIC findings and experience in eradicating those pathogens, and/or on consultation with
clinical/medical microbiologists or infectious disease specialists.
Most laboratories in the Working Group members’ countries report an isolate’s susceptibility to be ‘susceptible’,
‘resistant’ or ‘intermediate’ according to either CLSI or EUCAST criteria. The ‘intermediate’ category has been used
in a number of various ways, for example as a buffer to prevent very major and major errors, to be used alongside
1524 FutureMicrobiol. (2017) 12(16) future science group
Reporting susceptibility to new antibiotics Special Report
the ‘resistant’ category to indicate results that are ‘nonsusceptible’ and to indicate pathogen or drug combinations
where an increased drug exposure may be necessary for optimal results [40]. However, antibiotic decision-making
is usually based on ‘susceptible’ or ‘resistant’ categories, since treatment choices for ‘intermediate’ susceptibility
are not clear-cut. ‘Intermediate’ should be interpreted as ‘nonsusceptible’ and physicians should thus choose an
alternative antibiotic to which the pathogen is susceptible. Nevertheless, reporting susceptibility as ‘intermediate’
can be useful in some cases, for example if two antibiotics are used synergistically (e.g., meropenem and colistin)
or to optimize the antimicrobial dosage regimen [41].
Selection of antibiotics for routine susceptibility testing depends primarily on the type of AST method, partic-
ularly if an automated panel is used. All antibiotics included on the panel are routinely tested, although not all of
those testedmay be reported; reports are usually issued only for first-line antibiotics. Until the cause of an infection is
known, initial therapy is generally empiric and guided by clinical presentation [20]. Clinical/medical microbiologists
and infectious disease specialists have an important role in advising physicians on the most appropriate antibiotics
to use, although decision-making can also involve infectious disease specialists and clinical pharmacologists. The
number and selection of antimicrobials tested is dependent on the organism isolated, infection site, the institution’s
formulary, physician requests and the automated panel or other testing methodology used [38]. Notably, the choice
of antibiotics to be tested via automated methods can be limited, including for new antibiotics that have yet to
be adopted by automated systems. While inclusion of an antibiotic on the hospital formulary is a key factor in
selection for susceptibility testing, availability on the automated panel, supply of the manual testing equipment
(disks or gradient strips) and requests from physicians are also important.
The inclusion of new antibiotics on commercial, automated test panels is often delayed for a considerable time
after approval [38,42]. However, agents from the same class with similar activities can be used as surrogate markers
(i.e., class representatives) to predict susceptibility of clinical isolates to new agents and/or to those not included in
routine testing. Clinical laboratories have used surrogate testing successfully for decades (see Table 1). Reliability
of a surrogate marker is typically analyzed by testing the categorical agreement between the susceptibility results
for the two agents, defining errors as very major (i.e., false-susceptibility), major (i.e., false-resistance) or minor
(i.e., the result for one agent was intermediate while the other agent was susceptible, nonsusceptible or resistant) [43].
However, it should be noted that the chance of a very major error is extremely low when the occurrence of resistant
isolates is rare or absent. Furthermore, in rare cases, susceptibility to a surrogate antibiotic might not reveal resistance
to the agent in question, for example a recently recognized, uncommon variant of fexA conferring resistance to
florfenicol, but not to chloramphenicol [44]. Such reports highlight the need to review the utility of surrogate
susceptibility testing as new data emerge.
Testing of new antibiotics: a focus on tedizolid
An alternative approach to susceptibility testing is needed for new antibiotics as their inclusion on commercial AST
panels is often delayed for several years after approval, which complicates testing and reporting [1]. Despite inclusion
on hospital formulary, the use of new antibiotics may be restricted for some months, which limits the opportunity
for physicians to gain clinical experience. This may be difficult to explain to physicians if the antibiotic is already
included in clinical practice guidelines. Consequently, clinical/medical microbiologists have a responsibility to
provide clinically relevant information to physicians and explain why it is or is not appropriate to use an antibiotic.
Additional barriers to susceptibility testing of new antibiotics include: problems with the availability and regular
supply of materials required for manual testing; not being included on the hospital formulary; lack of breakpoints
for certain pathogens; and the increased workload and costs associated with supplementary testing. Working
Group members report that novel antibiotics will most likely be routinely tested once they become available on an
automated panel(s). Until then, susceptibility testing for new agents is performed manually, but often undertaken
only upon physician request. In the short term, surrogate agents (that are included on automated panels) can be
used to predict pathogen susceptibility to new antibiotics [1].
Several methods are currently available to test tedizolid susceptibility, including the use of linezolid as a surrogate
antibiotic. Linezolid susceptibility is considered a highly reliable surrogate for tedizolid susceptibility; a high
categorical agreement has been reported between the susceptibility of tedizolid and linezolid; and the very major
error rates were low (≤0.2%) for all organisms tested [42]. Based on these findings, EUCAST recommends that
isolates susceptible to linezolid can be reported as susceptible to tedizolid [47]. For isolates intermediate/resistant
to linezolid, an MIC test must be performed to confirm susceptibility or resistance to tedizolid. Most laboratories
in Working Group members’ countries would add to the AST report a ‘tedizolid susceptible’ result based on a
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Table 1. Antibiotics used as surrogate agents in clinical practice.
Surrogate agent Pathogen Antibiotic(s) for which susceptibility is
reported
Ref.
Ampicillin Enterococci Amoxicillin-clavulanic acid,
ampicillin-sulbactam, piperacillin,
piperacillin-tazobactam
[45]
Cefepime H. influenzae Ceftaroline [46]
Cefoxitin Staphylococci Oxacillin [45]
Cephalosporins† [47]
Ceftazidime H. influenzae Ceftaroline [46]
Ceftriaxone S. pneumoniae Ceftaroline [46]
H. influenzae Ceftaroline [46]
Cephalothin Enterobacteriaceae Cefapirin, cephradine, cefaclor,
cefadroxil, cefpodoxime, cephalexin
and loracarbef
[45,48]
Ertapenem Enterobacteriaceae
Haemophilus spp.
S. pneumoniae
Doripenem [49]
Erythromycin Streptococci Azithromycin, clarithromycin and
dirithromycin
[45]
Imipenem S. aureus Ceftaroline [46]
P. aeruginosa Doripenem [50]
Levofloxacin S. pneumoniae Fluoroquinolones [51]
Linezolid Staphylococci
Enterococci
Streptococci
Streptococcus anginosus group
Tedizolid [42]
Staphylococci
Streptococci
[47]
Meropenem S. aureus Ceftaroline [46]
P. aeruginosa Doripenem [50]
Nalidixic acid H. influenzae
M. catarrhalis
Ciprofloxacin, levofloxacin,
moxifloxacin and ofloxacin
[47]
Norfloxacin Staphylococci
Streptococci
Ciprofloxacin, levofloxacin,
moxifloxacin and ofloxacin
[47]
Oxacillin S. aureus Cefazolin, ceftriaxone, ceftaroline and
nafcillin
[52]
Penicillin Enterococci Ampicillin, amoxicillin,
amoxicillin-clavulanic acid,
ampicillin-sulbactam, piperacillin,
piperacillin-tazobactam
[45]
Teicoplanin Staphylococci
Streptococci
Dalbavancin [53]
Tetracycline Vibrio cholerae Doxycycline‡ [45]
Staphylococci
Streptococci
H. influenzae
M. catarrhalis
N. gonorrhoeae
Doxycycline and minocycline [47]
Vancomycin Staphylococci
Streptococci
Dalbavancin [53,54]
Staphylococci
Streptococci
Dalbavancin and oritavancin [47]
Staphylococci
Streptococci
Enterococci
Oritavancin [55]
†‡Not cefixime, ceftazidime, ceftibuten and ceftolozane-tazobactam.
Disk diffusion should not be used for doxycycline due to poor correlation with minimum inhibitory concentration results.
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surrogate ‘linezolid susceptible’ actual testing result, but would not report a ‘tedizolid resistance’ result without
knowledge of the results of actual tedizolid susceptibility testing. AST results are typically discussed with the treating
physician before reporting so as not to delay clinical decision-making. The CLSI recommends that tedizolid and
linezolid are included in the Group B optional primary test and reported selectively [45]. Additional methods
available for tedizolid susceptibility testing include MIC test strips (LiofilchemR©, Liofilchem s.r.l., Roseto, Italy)
and a broth microdilution device (SensititreTM Thermo ScientificTM, Thermo Fisher Scientific Inc., Cleveland,
OH, USA) developed primarily for research purposes [56]. Use of 20 μg disk diffusion has been approved by the
CLSI for measurement of tedizolid susceptibility as a quality control measure [45]. To obtain susceptibility results
in microbiology laboratories, currently a more practicable 2 μg disk diffusion method is under development, in
addition to automated susceptibility testing panels. It should be noted that methodological testing issues have
been observed with tedizolid and linezolid which suggest that 80% inhibition MIC end point criterion should be
employed for testing both agents [57].
Tedizolid has demonstrated more potent activity in vitro than linezolid against Gram-positive bacteria, including
MRSA and vancomycin-resistant enterococci, as well as noninferiority in patients with skin and skin structure
infections [11–14,18–19]. Of note, tedizolid retains in vitro activity against S. aureus and other Gram-positive bacterial
strains that harbor the cfr-gene encoded methylase enzyme [58,59]. This methylase enzyme confers resistance against
five structurally different antibiotic classes (e.g., clindamycin in the lincosamide class, chloramphenicol in the
phenicol class, and linezolid, but not tedizolid, in the oxazolidinone class) [58]. The encoded enzyme methylates the
A2053 nucleotide in the peptidyl-transferase center of the 23S ribosomal RNA, which is a very highly conserved site,
and this methylation prevents binding of antibiotics to peptidyl-transferase center [60]. Importantly, chromosomal
mutations in Domain V of rRNA or ribosomal L3 protein identified to date were demonstrated to confer resistance
to both linezolid and tedizolid, stressing the need to test tedizolid susceptibility [59,61]. The Working Group stresses
the importance of providing tedizolid susceptibility results in order to guide clinicians in selecting the most effective
agent for their patients, and to provide an alternative option in cases of resistance development. They recommend
the adoption of EUCAST guidelines on use of linezolid as a surrogate to predict tedizolid susceptibility [47], in
order to enable routine inclusion of tedizolid in AST reports by microbiology laboratories. The Working Group
also advocates having tedizolid MIC test strips in place in laboratories so that it is possible to perform tedizolid
susceptibility testing, particularly when nonsusceptibility to linezolid is detected. Furthermore, they highlight the
importance of a surveillance program for monitoring resistance and appropriate antibiotic use of all new antibiotics.
Conclusion & recommendations
TheWorking Group has highlighted the difficulty in acquiring sufficient clinical data to enable clinical breakpoints
for new antibiotics to be established and the time taken (possibly up to 5 years) for such agents to be included
in automated testing panels, which are often used for routine susceptibility testing. Policy makers should aim to
minimize delays in the adoption of new breakpoints for antibiotics against emerging pathogens, particularly when
containment of spread is vital; delays should be reduced to less than 1.5 years whenever possible [62]. However, to
guide clinicians on appropriate treatment, it is critical that the susceptibility of new antibiotics is reported. Using
tedizolid as an example, if it is not possible to determine susceptibility, data may be extrapolated by using linezolid
as a surrogate, allowing subsequent appropriate use of tedizolid. In situations identified by a clinical/medical
microbiologist (e.g., linezolid nonsusceptible strains of Gram-positive bacteria) an appropriate manual test for
tedizolid will be necessary (Figure 1). Susceptibility testing and routine reporting of selected new antibiotics can
be desirable to ensure that clinicians make the appropriate choices for the management of infection, and that
development of resistance is closely monitored as new agents become available.
Future perspective
At present, there is a considerable time lag between approval of new antibiotics, availability of clinical breakpoints
and inclusion on commercial AST panels. It is hoped that closer coordination in the coming years between those
involved in drug development and AST panels and regulatory authorities will shorten this delay, enabling routine
testing of new agents at the time of approval. In the meantime, to ensure appropriate antibiotic choice, it is essential
that laboratories use the available tools to enable them to report susceptibility of new antibiotics.
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New antibiotic:
tedizolid
Surrogate
antibiotic: linezolid
Linezolid
susceptible
Report linezolid
and tedizolid
susceptibility
Linezolid   
nonsusceptible
Recommend: 
use a tedizolid MIC
test strip†
Tedizolid
susceptible
Tedizolid  
nonsusceptible
Report tedizolid
susceptible,
linezolid resistant
Report linezolid and tedizolid
resistant − send to Reference
Laboratory for confirmation of
unusual phenotype 
S NS
S NS
Figure 1. Recommended approach for routine reporting of susceptibility of new antibiotics, for example, tedizolid.
†Use of broth microdilution is also applicable.
As recommended by published evidence/according to susceptibility testing guidance [42,47].
NS: Nonsusceptible; S: Susceptible.
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Executive summary
Background
 A Working Group of clinical/medical microbiologists from Brazil, Canada, Mexico, Saudi Arabia, Russia and the
UK has made recommendations for optimal routine testing and reporting of susceptibility to new antibiotics,
using the novel oxazolidinone antibiotic tedizolid as an example.
Overview of testing methodology
 Most laboratories use automated testing systems (e.g., Vitek2, Microscan and Phoenix) routinely for susceptibility
testing, with manual testing (e.g., EUCAST or CLSI disk diffusion, broth microdilution or gradient testing
[e.g., E-test R©]) used to confirm the results and minimum inhibitory concentrations (MICs).
 The inclusion of new antibiotics on commercial, automated test panels and/or the availability of susceptibility
testing materials, are often delayed for a considerable time after approval; however, agents from the same class
with similar activities can be used as surrogate markers to predict susceptibility of clinical isolates to new agents
and/or to those not included in routine testing.
Testing of new antibiotics: a focus on tedizolid
 Several methods are currently available to test tedizolid susceptibility: use of linezolid as a surrogate antibiotic,
MIC test strips (Liofilchem R©, Liofilchem s.r.l., Roseto, Italy) and a broth microdilution device (SensititreTM Thermo
ScientificTM, Thermo Fisher Scientific Inc., Cleveland, OH, USA).
 Adoption of EUCAST guidelines on use of linezolid as a surrogate to predict tedizolid susceptibility is
recommended in order to enable routine inclusion of tedizolid in antimicrobial susceptibility testing reports;
having tedizolid MIC test strips in place in laboratories is also advocated so that tedizolid susceptibility testing
can be performed when nonsusceptibility to linezolid is detected.
Conclusion & recommendations
 It can take up to 5 years for new antibiotics to be included in automated testing panels yet it is critical that the
susceptibility of these agents is reported.
 If it is not possible to determine susceptibility, data may be extrapolated by using a surrogate, for example,
linezolid susceptibility as a reliable surrogate for tedizolid.
 Susceptibility testing and routine reporting of selected new antibiotics is desirable to ensure that clinicians make
the appropriate choices for the management of infection.
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